Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is a immune modulator blocking its interactions could strengthen immune cells' attack on cancer.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
- Fano
- Italy
Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.
Request full access to PitchBookDiatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.
Request full access to PitchBook